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Background: Zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) have been
successfully used to knock out endogenous genes in stem cell research. However, the deficiencies of current
gene-based delivery systems may hamper the clinical application of these nucleases. A new delivery method that
can improve the utility of these nucleases is needed.
Results: In this study, we utilized a cell-penetrating peptide-based system for ZFN and TALEN delivery. Functional
TAT-ZFN and TAT-TALEN proteins were generated by fusing the cell-penetrating TAT peptide to ZFN and TALEN,
respectively. However, TAT-ZFN was difficult to purify in quantities sufficient for analysis in cell culture. Purified
TAT-TALEN was able to penetrate cells and disrupt the gene encoding endogenous human chemokine (C-C motif)
receptor 5 (CCR5, a co-receptor for HIV-1 entry into cells). Hypothermic treatment greatly enhanced the TAT-TALEN-
mediated gene disruption efficiency. A 5% modification rate was observed in human induced pluripotent stem cells
(hiPSCs) treated with TAT-TALEN as measured by the Surveyor assay.
Conclusions: TAT-TALEN protein-mediated gene disruption was applicable in hiPSCs and represents a promising
technique for gene knockout in stem cells. This new technique may advance the clinical application of TALEN
technology.
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Zinc-finger nucleases (ZFNs) and transcription activa-
tor-like effector nucleases (TALENs) are two types of
artificial site-specific nucleases that are generated by fus-
ing the DNA cleavage domain of the FokI restriction
endonuclease with a custom-designed DNA biding
domain. In ZFNs and TALENs, these DNA-binding
domains are the C2H2 zinc-finger motif [1] and the tran-
scription activator-like effector (TALE) domain respect-
ively [2]. Because the FokI nuclease domain functions as
a dimer, ZFNs and TALENs are typically used in pairs.
These chimeric nucleases induce DNA double-strand
breaks at defined sites in living cells that can be repaired
via homology-directed repair (HDR) pathway, which
utilizes a homologous donor DNA, or imprecise nonho-* Correspondence: chen_xiaoping@gibh.ac.cn
†Equal contributors
1Laboratory of Pathogen Biology, State Key Laboratory of Respiratory Disease,
Center for Infection and Immunity, Guangzhou Institutes of Biomedicine and
Health, Chinese Academy of Sciences, Guangzhou 510530, China
2Guangzhou Science Park, Guangzhou 510530, P. R. China
© 2013 Ru et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the ormologous end joining (NHEJ) pathway [3]. These engi-
neered nucleases have been widely used to modify en-
dogenous genes in human stem cells [4-7]. However,
gene-based delivery systems are problematic. In particu-
lar, the use of viral vectors entails the risk of insertional
mutagenesis [8], whereas plasmid DNA has cell-type re-
strictions and cytotoxicity.
Cell-penetrating peptides (CPPs), also known as pro-
tein transduction domain (PTD) peptides, have been
used to deliver a variety of cargoes (including drug mole-
cules, nucleic acids, liposome nanoparticles and large
proteins) into cells both in vivo and in vitro and have
therefore shown great promise as therapeutic delivery
mechanisms for the treatment of several diseases [9].
The CPP delivery system has various advantages includ-
ing applicability to all cell types, high transduction effi-
ciency and controlled administration. Among the CPPs,
TAT (YGRKKRRQRRR) is the most widely investigated
and widely used peptide. TAT is a short peptide consis-
ting of 11 amino acids from the human immunodefi-
ciency virus-1 (HIV-1) TAT protein and is rich inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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charged and hydrophilic [10]. Since the first use of TAT
as a delivery vehicle for introducing molecules into cells
in the late 1990s, numerous studies have reported the
use of TAT for the delivery of various biomolecules
(especially proteins) into cells in the form of TAT fusion
proteins or TAT-protein conjugates [11]. Use of TAT as
a delivery vehicle has been considered as one of the
most promising gene-free strategies.
In this study, we designed TAT-ZFN and TAT-TALEN
fusion proteins by in-frame cloning. We succeeded in
purifying functional TAT-TALEN proteins, and demon-
strated their cell penetrating properties. When incubated
with living cells, TAT-TALENs efficiently disrupted the
endogenous CCR5 gene under hypothermic conditions
in a dose-dependent manner and we observed a disrup-
tion efficiency of up to 5% in human induced pluripotent
stem cells (hiPSCs).
Results
Purification and activity testing of TAT-ZFNs and
TAT-TALENs
The structure of the TAT-ZFN construct is shown in
Figure 1A. Soluble proteins were purified as described in
Methods. TAT-ZFN purification was greatly limited by
its low protein expression level and low binding affinity;Figure 1 Purification of TAT-ZFNs. (A) Schematic diagram of the TAT-ZF
conditions. (C) Western blot analysis of expressed TAT-ZFNs using an anti-H
native conditions. The negative control is indicated by “-”. The recognition
therefore, Hpy188III was used as the positive control (+).thus, only a small amount of TAT-ZFN could be obtained
(Figure 1B). Because the purification tag could be detected
by anti-His antibodies (Figure 1C), we speculated that the
His tag was likely to be hidden by the tertiary structure of
the native protein. Nevertheless, TAT-ZFNs showed spe-
cific nuclease activity in vitro (Figure 1D).
No problems were encountered with TAT-TALEN
purification. Standard TALEN was also constructed and
purified for use as a control in subsequent experiments.
The structure of standard TALEN and TAT-TALEN is
illustrated in Figure 2A. The purified proteins were visu-
alized using sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) with Coomassie Brilliant
Blue staining (Figure 2B). The in vitro DNA cleavage
assay demonstrated that both purified standard TALEN
and TAT-TALEN were functional (Figure 3). Notably, a
high TALEN concentration resulted in non-specific
DNA cleavage.
Transduction of proteins into living cells
To evaluate the ability of the purified proteins to pene-
trate cells, HeLa cells were treated with 1.5 μM TALEN
proteins for 1 hour at 37°C and subsequently washed
with 1 mg/ml heparin to remove proteins bound to the
cell surface. Immunoblotting of the treated HeLa lysate
showed that TALEN itself could not penetrate the cells;N construct. (B) SDS-PAGE analysis of TAT-ZFNs purified under native
is antibody. (D) In vitro activity testing of TAT-ZFNs purified under
sequence of Hpy188III is located within the ZFN recognition sequence;
Figure 2 Purification of standard TALENs and TAT-TALENs. (A) Schematic diagram of standard TALENs and TAT-TALENs. (B) SDS-PAGE
analysis of four TALEN proteins stained with Coomassie blue after purification.
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110 kD TALEN into the cells (Figure 4).
CCR5 disruption in HeLa cells and hiPSCs
HeLa cells were subjected to treatment with TALENs at
37°C for 1 hour and then continuously cultured at 37°C
for 24 hours before the next treatment. After three treat-
ment cycles, a Surveyor nuclease assay was performed to
evaluate gene disruption. TAT-TALENs disrupted CCR5
at 37°C in a dose-dependent manner, whereas standard
TALENs exerted no effects on CCR5 disruption. As
shown in Figure 5A, HeLa cells subjected to three con-Figure 3 Activity testing of purified standard TALENs and TAT-TALEN
cleavage products with lengths of 229 bp and 277 bp.secutive treatments with 3 μM TAT-TALEN proteins
showed a modification frequency of 3% as measured by
the Surveyor assay. This modification frequency in-
creased to 16% when the cells treated with TAT-TALEN
were incubated at 30°C. Standard TALENs still did not
disrupt CCR5 gene under hypothermic conditions. To
verify the reliability of the Surveyor assay, TAT-TALEN
mediated CCR5 disruption was confirmed by sequence
analysis of cloned CCR5 alleles amplified from treated
HeLa cells (Figure 5B).
To explore the potential of this method for practical
application, we evaluated the effects of CCR5 genes. Specific activity was determined based on the presence of two
Figure 4 Western blot analysis of lysate from the treated HeLa
cells using an anti-FLAG antibody. HeLa cells were incubated with
TALEN for 1 hour at 37°C and subsequently washed three times with
1 mg/ml heparin-PBS to remove proteins bound to the cell surface
before lysis.
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hypothermic conditions, hiPSCs subjected to three
consecutive treatments with 3 μM TAT-TALEN proteins
showed gene disruption frequencies of up to 5%
(Figure 5A). It is unknown whether cell membrane com-
position or endocytosis capabilities could explain the ob-
served differences between HeLa cells and hiPSCs with
regard to CCR5 gene disruption frequency.Figure 5 Disruption of endogenous genes by direct delivery of TALEN
HeLa cells and hiPSCs subjected to three consecutive treatments with TALE
cleavage at mismatches produces products of 254 bp and 277 bp. (B) Repr
consecutive treatments with 3 μM TAT-TALEN proteins under hypothermic
aligned with the cleavage site (wild type [WT]). Underlines highlight bindinTAT-TALEN cytotoxicity analysis
To examine the cytotoxicity of TAT-TALENs, the prolifer-
ation of HeLa cells and hiPSCs treated with TAT-TALENs
was measured. We observed a decrease in the prolifera-
tion of each cell type after three consecutive treatments
with TAT-TALENs (Figure 6). Cytotoxicity was also dose-
dependent, suggesting that consecutive low doses might
be required to minimize potential toxic effects.
Discussion
Targeted genomic engineering in stem cells at desired
endogenous gene loci by ZFNs or TALENs has signifi-
cant therapeutic implications [4]. The correction of
disease-causing mutations in patient-derived stem cells
is a goal of curative regenerative medicine. The disrup-
tion of a normal gene in stem cells can also be beneficial
for the treatment of certain diseases. CCR5 is a major
co-receptor for HIV-1 that is present on the surface of
target cells [12]. Currently, autologous transplantation
of CCR5-deficient human hematopoietic stem cells
(hHSCs) has been a promising strategy for acquired im-
munodeficiency syndrome (AIDS) treatment [13-17].
Notably, HIV-1 can establish latent viral reservoirs in
hHSCs [18] prior to genome engineering; thus, cautionproteins. (A) Frequency of endogenous CCR5 gene disruption in
N proteins as determined by the Surveyor assay. Surveyor nuclease
esentative sequence analysis of the CCR5 locus in HeLa cells after three
conditions. Multiple deletions (dashed) and insertions (lowercase) are
g sites for TALEN L and TALEN R.
Figure 6 Proliferation of HeLa cells and iPSCs subjected to
three consecutive treatments with various concentrations of
TAT-TALEN proteins. Values are normalized to mock treated cells.
Error bars, s.d. (n = 3).
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successfully disrupted the CCR5 locus of hiPSCs using
ZFNs and demonstrated that these CCR5-disrupted
hiPSCs can differentiate into CD34+ cells with multipo-
tency in vitro [19]. This work contributes to the ad-
vancement of patient-specific therapies with genetically
modified hiPSCs produced from the healthy tissues of
HIV-infected patients. However, some problems such as
safety concerns regarding the gene-based delivery
method of ZFNs and TALENs need to be addressed
[8,20]. In addition to mRNA delivery system, our TAT-
TALEN protein provides an alternative to eliminate the
risk of insertional mutagenesis and expands the range of
cell types that the nucleases can be applied to modify.
The concept of CPP-ZFN proteins has been proposed
previously [21,22]. However, we failed to utilize TAT-
ZFN to modify the endogenous gene because of a purifi-
cation problem. Recently, a study by Gaj and colleagues
demonstrated the intrinsic cell-penetrating capabilities
of standard ZFN proteins and their ability to successfully
modify CCR5 in living cells [23]. Compared with ZFNs,
TALENs are more mutagenic [24] and more specific
[25]; additionally, the design and assemble of TALENs is
very simple and straightforward [26,27]. In all these as-
pects, TALENs are superior to ZFNs.
We utilized TAT-TALEN to successfully disrupt en-
dogenous CCR5 in HeLa cells and hiPSCs. It has been
reported that hypothermia treatment improves ZFN-
driven [28] and TALEN-driven [29] gene disruption in
human cells transfected with eukaryotic expression vec-
tors. We found that hypothermic treatment was also
effective in cells transduced with TAT-TALENs. A high
TALEN concentration may lead to an increase in
off-target cleavage events in cells; cells treated withexcessive amounts of TAT-TALENs are likely to die as a
result of non-specific genome cleavage. This effect may
account for the moderate cytotoxicity observed in this
experiment. In our study, TAT was fused to the
N-terminus of TALEN. It is unknown whether shifting
the TAT peptide to the C- terminus of TALEN or using
other CPPs such as polyarginine could further enhance
protein penetration efficiency; however, similar adjust-
ments need to be considered in future studies.
In summary, we generated functional TAT-TALEN
proteins that were capable of penetrating cells. These
constructs were used to efficiently disrupt CCR5 in HeLa
cells and hiPSCs. Combined with our previous work, this
gene-free delivery system has great potential for the clin-
ical application of CCR5-disrupted hiPSCs. In addition,
this new TALEN delivery method may be applied to the
gene therapy for several monogenic diseases as well, a
circumstance in which a DNA donor template is needed.
Methods
Construction of prokaryotic expression plasmids
ZFN mammalian expression vectors were previously
constructed in our lab [19]. TALEN mammalian expres-
sion vectors were constructed as described [26,29]. The
corresponding prokaryotic expression plasmids were
constructed as follows: encoding sequences of ZFN and
TALEN were cloned from their mammalian expression
vectors. TAT-encoding sequences were introduced by
primer design. All primer sequences are provided in
Additional file 1: Table S1. The PCR products were
digested with NdeI and BamHI for (ZFN) or NdeI and
HindIII (for TALEN), and the digested products were
inserted into pET28a (Novagen) to yield the following
six plasmids: pET.TAT-ZFNL, pET.TAT-ZFNR, pET.
TAT-TALENL, pET.TAT-TALENR, pET.TALENL, pET.
TALENR. L and R stand for left and right, respectively.
Left ZFN (or TALEN) and right ZFN (or TALEN)
constitute a functional ZFN (or TALEN) pair. Proper
construction of each expression cassette was verified by
sequence analysis. The amino acid sequences of each
protein are provided in Additional file 1: Table S2.
Expression and purification of fusion proteins
Recombinant expression plasmids were transformed
into competent Escherichia-coli BL21 (DE3) cells. LB
medium (40 ml) supplemented with 100 μg/ml kanamy-
cin was inoculated with a single colony and incubated
overnight at 37°C with shaking. On the following day,
the overnight culture was diluted 50-fold into fresh LB
medium supplemented with 100 μg/ml kanamycin
and incubated at 37°C with shaking until the optical
density at 600 nm (OD600) reached 0.5. The culture was
then incubated at 16°C for 1 hour. Protein synthesis
was induced by the addition of isopropyl β-d-1-
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0.7 mM, and the culture was grown overnight at 16°C
with shaking. The cells were harvested and lysed five
times using a French press (JN-3000 PLUS, JNBIO) at
10,000 psi in lysis buffer (25 mM Tris–HCl, pH 8.0,
300 mM NaCl, 5% V/V glycerol) at 4°C. After the cell
debris was removed by centrifugation at 20,000 g for
30 minutes, TALEN proteins in the soluble fraction were
purified using Ni-NTA agarose resin (QIAGEN) and
eluted with elution buffer (lysis buffer with 500 mM
imidazole, pH 8.0). For TAT-ZFN expression and purifi-
cation, 100 μM ZnCl2 was added to all solutions.
Each protein was desalted using PD-10 columns (GE
Healthcare) into PBS (pH 7.4) with 20% glycerol and
sterilized by filtration through a 0.22 μM filter. The pro-
tein was then aliquoted and stored at −80°C. Protein
purity was assessed by SDS-PAGE, and the total protein
concentration was determined using a BCA protein
assay kit (Beyotime, China). The total protein concentra-
tions of standard TALEN and TAT-TALEN were between
0.9 and 1.2 mg/ml and between 0.3 and 0.5 mg/ml,
respectively.
In vitro activity of purified proteins
Because the recognition sites of ZFN and TALEN are
distinct from each other, CCR5 loci were amplified sep-
arately from the human genomic DNA with different
primer pairs (Primer Pair 1 for ZFNs and Primer Pair 2
for TALENs). The substrate DNA was incubated with
ZFN or TALEN in NEB buffer 4 for 1 hour at 37°C [30].
Cleavage products were separated by agarose gel electro-
phoresis (1.5%) or polyacrylamide gel electrophoresis
(8%) in 1 × TBE buffer and stained with ethidium bro-
mide solution.
Cell culture
HeLa cells were seeded onto 48-well plates at a density
of 5 × 104 cells per well and cultured in a humidified
atmosphere containing 5% CO2 at 37°C. Cells were
maintained in high-glucose DMEM (HyClone) contai-
ning 10% fetal bovine serum (FBS) and 1% (v/v)
penicillin-streptomycin.
hiPSCs were induced from the urine cells of a healthy
individual using episomal vectors. Initial populations
were seeded onto 48-well plates at the proper density
and grown until cell confluence reached 60-70%. These
cells were maintained in a feeder-free culture system
using mTesR1 (Stem Cell Technologies, Vancouver, BC,
Canada) and Matrigel (BD Bioscience, Bedford, MA)
with 1% (v/v) penicillin-streptomycin.
Protein treatments
TALEN proteins, including standard TALENs and
TAT-TALENs were prepared for treatment as follows:TALEN proteins were diluted into serum-free high-
glucose DMEM. The cells were washed with serum-free
medium and incubated with TALEN proteins for 1 hour
at 37°C. After the initial treatment, the cells were
washed and maintained at 37°C or shifted to 30°C for
24 hours before the next treatment. This process was re-
peated three times over four consecutive days.Western blot analysis to determine protein internalization
HeLa cells were treated with either 1.5 μM TALEN or
1.5 μM TAT-TALEN for 1 hour at 37°C and then
washed three times with 1 mg/ml heparin-PBS to
remove proteins bound to the cell surface. After
trypsinization, the cells were collected and lysed in RIPA
lysis buffer (Beyotime) and subsequently boiled in the
presence of loading buffer (50 mM Tris–HCl, pH 6.8,
100 mM dithiothreitol, 2% sodium dodecyl sulfate
(SDS), 20% glycerol and 0.2 mg/mL bromophenol blue)
for 10 minutes and subjected to electrophoresis using
10% SDS-PAGE. The gel was transferred to a polyviny-
lidene difluoride membranes using a Trans-blot SD
Semi-Dry Electrophoretic Transfer Cell (Bio-Rad La-
boratories, Hercules, CA). TALENs were verified using
monoclonal anti-FLAG M2 antibodies (Sigma, 1:1000
dilution) and secondary HRP-labeled goat anti-mouse
antibodies (Sigma, 1:5000 dilution). The internal loa-
ding control, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), was detected with peroxidase-conjugated
anti-GAPDH antibody. The western blots were devel-
oped with DAB substrate according to the manufac-
turer’s instructions.Surveyor nuclease assay
Genomic DNA was extracted from TALEN-treated cells
with a DNeasy Blood and Tissue Kit (QIAGEN). The
CCR5 locus was amplified by nested PCR, and the se-
quences of the outer and inner primers are provided in
Additional file 1: Table S1. After amplification of the CCR5
locus using Platinum® Taq DNA Polymerase (Invitrogen), a
Surveyor nuclease assay was performed following the in-
structions included with the SURVEYOR Mutation Detec-
tion Kit (Transgenomic). Analysis of the gene disruption
frequency was performed as described [31]. The gel image
was processed with the ImageJ software.Cell proliferation assay
HeLa cells and hiPSCs were seeded onto 48-well plates
at the optimal densities. The cells were then treated with
TAT-TALEN proteins as described above. Cytotoxicity
assays were conducted using the Cell Counting Kit-8
(Dojindo Molecular Technologies, Inc.) according to the
manufacturer’s instructions.
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Genomic DNA from TAT-TALEN-treated HeLa cells
was isolated with the DNeasy Blood and Tissue Kit
(QIAGEN). The CCR5 locus was amplified by PCR with
the primers BamHI-5’hCCR5 and HindIII-3’hCCR5.
Subsequently, the PCR products were cloned into
PUC19 plasmids using the BamHI and HindIII restric-
tion sites. CCR5 disruption was confirmed by sequence
analysis of individual cloned transformants.
Ethical approval
This experiments was approved by the Human Subject
Research Ethics Committee (IRB), Guangzhou Institutes
of Biomedicine and Health, Chinese Academy of Sci-
ences with the reference number: GIBH-IRB02-2009002.
Additional file
Additional file 1: Table S1. The sequences of primers used in this
study. Table S2. The amino acid sequences of the ZFN and TALEN
proteins used in this study.
Competing interests
The authors confirm that there are no competing interests associated with
this publication and there has been no significant financial support that
could have influenced the outcome of this work.
Authors’ contributions
RR and YY conceived and designed the experiment, collected and/or
assembled the data, performed data analysis and interpretation, and wrote
the manuscript. SY, WX and BY performed cell culture and molecular
cloning. SZ and LQ assisted with manuscript revisions. XC supervised the
work, revised the manuscript and approved the final version of the
manuscript prior to submission for publication. All Authors read and
approved the final manuscript
Acknowledgments
We are grateful to Miguel A. Esteban and his group for supplying the hiPSCs.
This work was financially supported by the National Science and Technology
Major Project (2013ZX10001-004-002-004) and the National Natural Science
Foundation of China (No. 81200398).
Received: 26 March 2013 Accepted: 3 June 2013
Published: 18 June 2013
References
1. Mandell JG, BarbasIII CF: Zinc Finger Tools: custom DNA-binding domains for
transcription factors and nucleases. Nucleic Acids Res 2006, 34:W516–523.
2. Li T, Yang B: TAL Effector Nuclease (TALEN) Engineering. Methods Mol Biol
2013, 978:63–72.
3. Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A,
Bogdanove AJ, Voytas DF: Targeting DNA double-strand breaks with TAL
effector nucleases. Genetics 2010, 186:757–761.
4. Collin J, Lako M: Concise review: putting a finger on stem cell biology:
zinc finger nuclease-driven targeted genetic editing in human
pluripotent stem cells. Stem Cells 2011, 29:1021–1033.
5. Zou J, Maeder ML, Mali P, Pruett-Miller SM, Thibodeau-Beganny S, Chou BK,
Chen G, Ye Z, Park IH, Daley GQ, Porteus MH, Joung JK, Cheng L: Gene
targeting of a disease-related gene in human induced pluripotent stem
and embryonic stem cells. Cell Stem Cell 2009, 5:97–110.
6. Hockemeyer D, Wang HY, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang
L, Santiago Y, Miller JC, Zeitler B, Cherone JM, Meng XD, Hinkley SJ, Rebar
EJ, Gregory PD, Urnov FD, Jaenisch R: Genetic engineering of human
pluripotent cells using TALE nucleases. Nat Biotechnol 2011, 29:731–734.7. Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K, Kuperwasser N,
Motola DL, Meissner TB, Hendriks WT, Trevisan M, Gupta RM, Moisan A,
Banks E, Friesen M, Schinzel RT, Xia F, Tang A, Xia Y, Figueroa E, Wann A,
Ahfeldt T, Daheron L, Zhang F, Rubin LL, Peng LF, Chung RT, Musunuru K,
Cowan CA: A TALEN Genome-Editing System for Generating Human
Stem Cell-Based Disease Models. Cell Stem Cell 2013, 12:238–251.
8. Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of
viral vectors for gene therapy. Nat Rev Genet 2003, 4:346–358.
9. Morris MC, Deshayes S, Heitz F, Divita G: Cell-penetrating peptides: from
molecular mechanisms to therapeutics. Biol Cell 2008, 100:201–217.
10. Vyas PM, Payne RM: TAT opens the door. Mol Ther 2008, 16:647–648.
11. Brasseur R, Divita G: Happy birthday cell penetrating peptides: already 20
years. Biochim Biophys Acta 2010, 1798:2177–2181.
12. Lopalco L: CCR5: From Natural Resistance to a New Anti-HIV Strategy.
Viruses 2010, 2:574–600.
13. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T,
Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK, Thiel E: Long-term
control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl
J Med 2009, 360:692–698.
14. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider
T: Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem
cell transplantation. Blood 2011, 117:2791–2799.
15. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G,
Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll
RG, Orange JS, Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes MC,
June CH: Establishment of HIV-1 resistance in CD4+ T cells by genome
editing using zinc-finger nucleases. Nat Biotechnol 2008, 26:808–816.
16. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB,
Gregory PD, Holmes MC, Cannon PM: Human hematopoietic stem/
progenitor cells modified by zinc-finger nucleases targeted to CCR5
control HIV-1 in vivo. Nat Biotechnol 2010, 28:839–847.
17. Symonds GP, Johnstone HA, Millington ML, Boyd MP, Burke BP, Breton LR:
The use of cell-delivered gene therapy for the treatment of HIV/AIDS.
Immunol Res 2010, 48:84–98.
18. Huddleston JE: HIV: HIV hides in haematopoietic stem cells. Nat Rev
Microbiol 2011, 9:311.
19. Yao Y, Nashun B, Zhou T, Qin L, Zhao S, Xu J, Esteban MA, Chen X:
Generation of CD34+ Cells from CCR5-disrupted Human Embryonic and
Induced Pluripotent Stem Cells. Hum Gene Ther 2011, 23:238–242.
20. Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, Harper LB,
Pauley CJ, Niu Z, Denisova L, Follmer TT, Rizzuto G, Ciliberto G, Fattori E,
Monica NL, Manam S, Ledwith BJ: Detection of integration of plasmid
DNA into host genomic DNA following intramuscular injection and
electroporation. Gene Ther 2004, 11:711–721.
21. Planel S, Salomon A, Jalinot P, Feige JJ, Cherradi N: A novel concept in
antiangiogenic and antitumoral therapy: multitarget destabilization of
short-lived mRNAs by the zinc finger protein ZFP36L1. Oncogene 2010,
29:5989–6003.
22. Nain V, Sahi S, Verma A: CPP-ZFN: a potential DNA-targeting anti-malarial
drug. Malar J 2010, 9:258.
23. Gaj T, Guo J, Kato Y, Sirk SJ, Barbas III CF: Targeted gene knockout by
direct delivery of zinc-finger nuclease proteins. Nat Methods 2012,
9:805–807.
24. Chen S, Oikonomou G, Chiu CN, Niles BJ, Liu J, Lee DA, Antoshechkin I,
Prober DA: A large-scale in vivo analysis reveals that TALENs are
significantly more mutagenic than ZFNs generated using context-
dependent assembly. Nucleic Acids Res 2013, 41:2769–2778.
25. Liu J, Li C, Yu Z, Huang P, Wu H, Wei C, Zhu N, Shen Y, Chen Y, Zhang B,
Deng WM, Jiao R: Efficient and specific modifications of the Drosophila
genome by means of an easy TALEN strategy. J Genet Genomics 2012,
39:209–215.
26. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, Baller JA,
Somia NV, Bogdanove AJ, Voytas DF: Efficient design and assembly of
custom TALEN and other TAL effector-based constructs for DNA
targeting. Nucleic Acids Res 2011, 39:e82.
27. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK: FLASH
assembly of TALENs for high-throughput genome editing. Nat Biotechnol
2012, 30:460–465.
28. Doyon Y, Choi VM, Xia DF, Vo TD, Gregory PD, Holmes MC: Transient cold
shock enhances zinc-finger nuclease-mediated gene disruption.
Nat Methods 2010, 7:459–460.
Ru et al. Cell Regeneration 2013, 2:5 Page 8 of 8
http://www.cellregenerationjournal.com/content/2/1/529. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE,
Leung E, Hinkley SJ, Dulay GP, Hua KL, Ankoudinova I, Cost GJ, Urnov FD,
Zhang HS, Holmes MC, Zhang L, Gregory PD, Rebar EJ: A TALE nuclease
architecture for efficient genome editing. Nat Biotechnol 2011, 29:143–148.
30. Tovkach A, Zeevi V, Tzfira T: A toolbox and procedural notes for
characterizing novel zinc finger nucleases for genome editing in plant
cells. Plant J 2009, 57:747–757.
31. Guschin DY, Waite AJ, Katibah GE, Miller JC, Holmes MC, Rebar EJ: A rapid
and general assay for monitoring endogenous gene modification.
Methods Mol Biol 2010, 649:247–256.
doi:10.1186/2045-9769-2-5
Cite this article as: Ru et al.: Targeted genome engineering in human
induced pluripotent stem cells by penetrating TALENs. Cell Regeneration
2013 2:5.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
